PH 15
Alternative Names: PH15; PH15 NSLatest Information Update: 02 May 2024
At a glance
- Originator Pherin Pharmaceuticals
- Class Nootropics
- Mechanism of Action Chemoreceptor cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cognition disorders
Most Recent Events
- 02 May 2024 PH 15 is still in phase II trials for Cognition disorders in Mexico
- 25 Apr 2024 Efficacy and adverse event data from the phase IIa Pilot study released by VistaGen Therapeutics
- 28 Jan 2024 No recent reports of development identified for phase-I development in Cognition-disorders in USA (Intranasal, Spray)